The core mission of the Yale Cancer Center is to reduce suffering from cancer by being a global leader in cancer research, care and education. Designated as a Comprehensive Cancer Center in 1974, the past five years have been a period of significant growth and restructuring. Dr. Thomas Lynch became the 6th Director of the YCC in April 2009 and recruited more than 80 new basic, population, translational and clinical scientists. In addition to appointing a new Deputy Director, Dr. Daniel DiMaio, Senior Leadership and cancer Center Administration was completely redesigned. For this submission 6 of 7 Research Programs are under new leadership. During the most recent funding period, the YCCs 260 members published 2751 articles, (21% intra-programmatic and 14% inter-programmatic) and hold $93M in total cancer funding (including $29M from NCI). Accrual to therapeutic clinical trials more than doubled over the past year. Driven by remarkable institutional support, significant expansion during the prior funding period included building the $450M Smilow Cancer Hospital, opening 7 regional Care Centers in Southern CT and acquiring the former Hospital St. Raphael to create the nation's 4th largest hospital. This clinical care expansion was matched by establishing the Yale Cancer Biology Institute at Yale's West Campus. A detailed strategic planning process has begun with a resultant strong emphasis on optimizing our research programs and shared resources and investing in translational research, cancer genetics, and tumor immunology. This 5-year request is to support an organizational framework that promotes and fosters basic and translational cancer research. The 7 Research Programs include: Cancer Genetics and Genomics, Cancer Immunology, Cancer Prevention and Control, Developmental Therapeutics, Molecular Virology, Radiobiology and Radiotherapy and Signal Transduction. Support is requested for 8 Shared Resources including Yale Center for Genome Analysis, Flow Cytometry, Yale Pathology Tissue Services, Cesium Irradiator, Rapid Case Ascertainment, Yale Center for Molecular Discovery, Biostatistics and the Clinical Trials Office. To support center goals and objectives support for Senior Leadership, Planning and Evaluation, Administration, and Developmental Funds is also requested.

Public Health Relevance

Cancer is a leading cause of mortality and morbidity in both in the United States and globally. The last decade has seen dramatic advances in elucidating the epidemiology, etiology and pathobiology of cancer. This application seeks to continue to explore and understand cancer while translating these findings into enhanced prevention and treatment for patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016359-35S4
Application #
8923513
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-07-01
Project End
2018-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
35
Fiscal Year
2014
Total Cost
$150,000
Indirect Cost
$59,910
Name
Yale University
Department
Dermatology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications